ArticleAlzheimer's research & therapy2021
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease.
Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human Leukocyte Antigen and microRNAs as Key Orchestrators of Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.Neurology · 2023Trial
- Associations between trajectories of plasma biomarkers for Alzheimer's disease, brain structures, and cognitive function: a prospective cohort study in the UK Biobank.Molecular psychiatry · 2026Article
- Neuropathological links between plasma p-Tau 181, white matter hyperintensity, and structural brain changes in aging.Quantitative imaging in medicine and surgery · 2026Article
- Phosphorylated Tau Biomarkers in Alzheimer's Disease: From Early Detection to Clinical Potential-A Comprehensive Review.Molecular neurobiology · 2026Review
- Article
- Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025Article
- A blood based mitochondrial functional index biomarker for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Proteome-Based Biomarkers for Alzheimer's Disease: Old Acquisitions and Innovative Proposals.International journal of molecular sciences · 2025Review
- Frequency of Microvascular Pathology and Hippocampal Atrophy on Magnetic Resonance Imaging in a Community Study of Alzheimer's Disease with Blood-Based Biomarkers.Annals of neurology · 2025Article
- Tau profiling across Alzheimer's disease staging reveals vulnerability to disease pathophysiology.European journal of nuclear medicine and molecular imaging · 2025Article
- Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co-Pathology in Lewy Body Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Distinctive volumetric associations between plasma p-tau181 and hippocampal formation structures across the Alzheimer's disease continuum.Journal of Alzheimer's disease : JAD · 2025Article
- The association between plasma and MRI biomarkers in dementia with lewy bodies.Alzheimer's research & therapy · 2025Article
- Systemic inflammation as a central player in the initiation and development of Alzheimer's disease.Immunity & ageing : I & A · 2025Review
- Atlas of Proteomic signatures of brain structure and its links to brain disorders.Nature communications · 2025Article
- Identification and Validation of New Molecular Subtypes within the Early and Late Mild Cognitive Impairment Stages of Alzheimer's Disease.medRxiv : the preprint server for health sciences · 2025Article
- Plasma protein risk scores for mild cognitive impairment and Alzheimer's disease in the Framingham heart study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Association of plasma biomarkers of Alzheimer's pathology and neurodegeneration with gait performance in older adults.Communications medicine · 2025Article
- Associations of plasma biomarkers with cerebral perfusion and structure in Alzheimer's disease.Translational psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer's disease.
methodsObservational data was obtained from the Alzheimer's Disease Neuroimaging Initiative, in which participants underwent plasma assessment and magnetic resonance imaging. Based on their clinical diagnosis, participants were classified as cognitively unimpaired and cognitively impaired. Linear regressions and linear mixed-effect models were used to test the cross-sectional and longitudinal associations between baseline plasma pTau181 and neurodegeneration using voxel-based morphometry.
resultsWe observed a negative correlation at baseline between plasma pTau181 and gray matter volume in cognitively unimpaired individuals. In cognitively impaired individuals, we observed a negative association between plasma pTau181 and both gray and white matter volume. In longitudinal analyses conducted in the cognitively unimpaired group, plasma pTau181 was negatively correlated with gray matter volume, starting 36 months after baseline assessments. Finally, in cognitively impaired individuals, plasma pTau181 concentrations were negatively correlated with both gray and white matter volume as early as 12 months after baseline, and neurodegeneration increased in an incremental manner until 48 months.
conclusionsHigher levels of plasma pTau181 correlate with neurodegeneration and predict further brain atrophy in aging and Alzheimer's disease. Plasma pTau181 may be useful in predicting AD-related neurodegeneration, comparable to positron emission tomography or cerebrospinal fluid assessment with high specificity for AD neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.